GoldenGolden
Advanced Search
Vaxart

Vaxart

Vaxart is a company deveoping oral vaccines founded in 2004 by Sean Tucker.

Vaxart is a clinical stage biotechnology company developing recombinant oral vaccines in tablet form. The company’s oral vaccines are developed with its proprietary platform called VAAST and are designed to activate the immune system of the gut which can generate broad systemic and local responses. Vaxart’s tablets can be stored at room temperature. The company is working on liquid formulations for young children and adults unable to ingest tablets.

The delivery platform uses a replication-incompetent adenovirus type 5 (Ad5) vector that delivers two payloads to cells in the mucosal epithelium of the small intestine. One payload is the gene that codes for a pathogen-specific antigen and the other is the gene for the Toll Like Receptor-3 (TLR-3) agonist. The TLR-3 agonist is an adjuvant that activates the innate immune system and has the ability to stimulate a broad immune response.

Vaxart has an H1 influenza oral tablet vaccine that completed a phase II clinical study in 2018. The company has a research collaboration with Janssen Vaccines & Prevention B.V. The company is working on a norovirus vaccine.

Vaxart’s investigational oral tablet vaccines have shown robust mucosal responses in humans. The company is working on a vaccine for the COVID-19 outbreak. Since the coronavirus primarily infects the respiratory tract, enhanced mucosal immune responses would be desirable in a vaccine for the novel coronavirus causing the COVID-19 outbreak.

Timeline

August 6, 2013
Vaxart raises a $20,000,000 series C round.
January 14, 2010
Vaxart raises a $3,500,000 series B round from Quantum Technology Partners.
November 15, 2007
Vaxart raises a $3,300,000 series A round from Quantum Technology Partners.

Funding rounds

People

Name
Role
LinkedIn

Andrea Zurek

Investor

Anurag (Anu) Nigam

Investor

David Madden

Advisor

Don Ross

Investor

Frank Willemsen

Investor

Gordon Chaffee

Investor

Jim Connor

Investor

Mason Ng

Investor

Michael Weickert

Investor

Rick Rasmussen

Investor

Salil Deshpande

Investor

Sand Hill Angels

Investor

Sarosh Kumana

Investor

Shaheen Shamsavari

Investor

Sherman Ting

Investor

Stephen Pollitt

Investor

Steve Bennet

Investor

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Alex Keown
April 28, 2021
BioSpace
Researchers are continuing to develop next-generation therapeutics and oral vaccines that could overcome some vaccine hesitancy. Here are some of the top producers.
BioSpace
April 23, 2021
BioSpace
Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Wheadon, M.D., to its Board of Directors.
Thomas Curwen
April 16, 2021
Los Angeles Times
Researchers are developing vaccines that could be taken as a capsule, a dissolvable tablet or a nasal spray. But the barriers to success are high.
Matthew Fox
February 3, 2021
Business Insider
"Neutralizing antibodies were not detected in serum and IgG responses were not detected in most subjects," Vaxart said in a press release.
Natalie Grover and Michael Safi
November 20, 2020
the Guardian
A mural at the Sinovac Biotech facilities in Beijing, which is conducting one of the four clinical trials for a Covid-19 vaccine that have been authorised in China. Photograph: Nicolas Asfouri/AFP via Getty
Natalie Grover and Michael Safi
November 20, 2020
the Guardian
With potential injectable vaccines estimated to be out of reach for two-thirds of world's population, scientists hope to find less-heat-sensitive formulations
BioSpace
November 12, 2020
BioSpace
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the third quarter of 2020 and provided a corporate update, including updates on its oral COVID-19 vaccine pre-clinical studies and clinical trials.
Krystle Vermes
November 12, 2020
BioSpace
Vaxart announced new data from its Hamster Challenge Study today, showing that its oral COVID-19 vaccine candidate can potentially reduce viral load and induce a significant immune response.
BioSpace
May 20, 2020
BioSpace
KindredBio Selected as Second Contract Manufacturing Organization GMP Production for Phase 1 Study Initiated

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.